LGP has been supplying the CBD50 to this trial, and remains the largest supplier with over 85% of the 3,000 participants expected to trial the product. The company said it was very pleased to be selected by the French Government to continue supplying its GMP manufactured medicinal cannabis products, and views the French medicinal cannabis market as a highly prospective opportunity for the company. LGP believes that supplying its cannabis product to this trial could position the company to supply any future French medicinal cannabis market and will provide the company with a key first mover advantage. France remains one of the largest potential medicinal cannabis markets in Europe, and the world. With the second largest population in the EU (65 million) and a total addressable market of $5.6 billion, LGP is optimistic that a future French medicinal cannabis market is one of the most prospective cannabis opportunities available globally. LGP regards its participation in the trial as a key first mover advantage in any such medicinal cannabis market. The trial is expected to conclude in March 2024.
Source: Stockhead